Business Context and Reporting Period
Company: ALX Oncology Holdings Inc. (ALXO)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 immune checkpoint. Its lead product candidate, evorpacept, is a fusion protein designed to block the "don't eat me" signal on cancer cells while avoiding the hematologic toxicities associated with other CD47 blockers. The company has no approved products and generates no product revenue.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(134.9) million | $(160.8) million |
| Operating Expenses | $142.5 million | $170.3 million |
| Research & Development (R&D) | $116.4 million | $141.8 million |
| General & Administrative (G&A) | $26.1 million | $28.5 million |
| Cash, Cash Equivalents & Investments | $131.3 million | $218.1 million |
| Accumulated Deficit | $(621.1) million | $(486.3) million |
| Debt Outstanding | $10.0 million (Term Loan) | $10.0 million (Term Loan) |
Note: The company reported no revenue for the period. Interest income was $9.4 million in 2024 compared to $10.6 million in 2023.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $26.0 million (16%) year-over-year, primarily driven by a $25.4 million decrease in R&D expenses.
- R&D Expense Decline: R&D expenses dropped 18% to $116.4 million. This was largely due to a $37.5 million decrease in clinical and development costs, as the majority of clinical trial material manufacturing was completed in early 2024. This decrease was partially offset by increases in stock-based compensation ($3.8 million), personnel costs ($3.7 million), and preclinical costs ($3.0 million).
- G&A Expense Decline: G&A expenses decreased 8% to $26.1 million, primarily due to a $3.0 million reduction in stock-based compensation expense.
- Liquidity Position: Cash, cash equivalents, and investments decreased by approximately $86.8 million from $218.1 million in 2023 to $131.3 million in 2024, reflecting operating cash outflows of $121.9 million.
Guidance, Outlook, and Risks
Clinical Progress and Outlook
- ASPEN-06 (Gastric/GEJ Cancer): Updated data presented in January 2025 showed an Overall Response Rate (ORR) of 41.3% for the Evo-TRP arm vs. 26.6% for the control arm in the Intent-to-Treat (ITT) population. In patients with confirmed HER2-positive expression, ORR was 48.9% vs. 24.5%.
- ASPEN-07 (Urothelial Cancer): Interim data showed an unconfirmed ORR of 61% for evorpacept plus enfortumab vedotin.
- Future Plans: The company intends to initiate Phase 2 studies in breast cancer (ASPEN-Breast) and Phase 1b studies in colorectal cancer (ASPEN-CRC) in 2025. It also plans to file an IND for its ADC program, ALX2004, in Q1 2025.
Liquidity and Capital Resources
Management believes existing cash, cash equivalents, and investments ($131.3 million) will fund operations into the fourth quarter of 2026. The company has a term loan facility with $25.0 million available at the lenders' sole discretion as of December 31, 2024, though milestone tranches were not fully accessible by year-end.
Risks and Contingencies
- Restructuring: In February 2025, the Board approved a workforce reduction of approximately 30% to prioritize the pipeline and preserve cash. Estimated expenses are $2.2 million, to be recognized in Q1 2025.
- Intellectual Property: Ongoing opposition proceedings regarding European patents (EP 2 429 574 and EP 2 995 315) held by third parties could potentially limit the company's ability to pursue evorpacept in certain indications in Europe.
- Regulatory: The company relies on third-party manufacturers and clinical trial sites; delays or failures in these areas could impact development timelines.
Key Facts for Investor Verification
- Cash Runway: Verify the company's ability to fund operations through Q4 2026 given the recent 30% workforce reduction and continued R&D burn rate.
- Clinical Data Validation: Confirm the statistical significance and durability of the ASPEN-06 trial results (ORR and PFS) as the company moves toward potential regulatory discussions.
- Debt Covenants: Review the terms of the $100 million term loan facility, specifically the conditions for accessing the remaining $25 million tranche and the impact of the recent restructuring on covenant compliance.
- IP Litigation Status: Monitor the outcome of the European Patent Office opposition hearings scheduled for late 2025 regarding third-party patents that may affect market access.
- Restructuring Costs: Track the actual recognition of the estimated $2.2 million severance and benefit costs in the Q1 2025 financial results.